NCT06455202Phase 3Active not recruiting

A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)

Study sponsor: Celldex Therapeutics

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2026-08-04Actual
Enrollment · participants976Actual
Source updated2026-11-12Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 2 fields changed

Completion date type changed

Before: Estimated. After: Actual.

Primary completion date changed

Before: Oct 2026. After: 4 Aug 2026.

Check registry source

· 3 fields changed

Participant count type changed

Before: Estimated. After: Actual.

Enrollment · participant count changed

Before: 915 participants (planned). After: 976 participants (actual).

Recruitment status changed

Before: Recruiting. After: Active not recruiting.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview